Dividing Opinion: Shire's Move to Purchase TKT
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 60 (Table of Contents)
Published: 1 Jun-2005
DOI: 10.3833/pdr.v2005.i60.667 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Shire Pharmaceutical Group's decision to buy the loss-making US biotech Transkaryotic Therapies (TKT) for US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS